IP Library Granted Patent US 8,088,624
Granted Patent B2
US 8,088,624 · App. 10/584,425 · Granted Jan 3, 2012

Method of detecting thrombosis by measuring von Willenbrand factor-cleaving protease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,088,624
App. No.
10/584,425
Granted
Jan 3, 2012
Kind
B2
Abstract

A method of detecting thrombosis or the degree of thrombophilia by measuring a von Willebrand factor cleaving protease, and a kit for detecting thrombosis or the degree of thrombophilia, comprising an antibody or a fragment thereof specifically binding to a von Willebrand factor-cleaving protease, are disclosed. The detection method and the detection kit have an excellent convenience, rapidity, and specificity.

Claims (10)

1. A method of determining the severity of thrombophilia, comprising measuring a von Willebrand factor-cleaving protease from a sample of bodily fluid from a patient suffering from one or more diseases selected from the group consisting of pulmonary embolism, cerebral infarction, veno-occlusive disease, and deep vein thrombosis, wherein said bodily fluid is selected from the group consisting of whole blood, blood plasma, and serum; and

correlating the quantitative level of von Willebrand factor-cleaving protease in the sample to that which would be present in a normal person, with a lower level present in the sample being indicative of an increased severity of thrombophilia;

wherein the measuring of von Willebrand factor-cleaving protease is performed by sandwich assay using at least one monoclonal antibody selected from the group consisting of WH10 accession number FERM BP-08174, WH63.1 accession number FERM BP-08175, and WH2-22-A1 accession number FERM BP-08483.

2. The method according to claim 1 , wherein the severity of thrombophilia is detected in a patient under a long-term treatment with dialysis accompanied by repeated shunt.

3. A method of determining the severity of thrombophilia in a patient, comprising:

collecting a sample of bodily fluid from said patient, said bodily fluid being selected from the group consisting of whole blood, blood plasma, and serum;

analyzing said sample by sandwich immunoassay using at least one monoclonal antibody selected from the group consisting of WH10 accession number FERM BP-08174, WH63.1 accession number FERM BP-08175, and WH2-22-A1 accession number FERM BP-08483 to quantitatively obtain the level of von Willebrand factor-cleaving protease present in the sample;

correlating the quantitative level of von Willebrand factor-cleaving protease in the sample to that which would be present in a normal person, with a lower level present in the sample being indicative of an increased severity of thrombophilia, wherein the patient is suffering from one or more diseases selected from the group consisting of pulmonary embolism, cerebral infarction, veno-occlusive disease, and deep vein thrombosis.

4. The method of claim 3 , where the bodily fluid is blood plasma.

5. The method of claim 3 , where the patient is a person under a long-term treatment with dialysis accompanied by repeated shunts.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2021
From: LSI MEDIENCE CORPORATION
To: KM BIOLOGICS CO., LTD.
Reel/Frame 057014/0692 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2019
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: KM BIOLOGICS CO., LTD.
Reel/Frame 048253/0886 →
CHANGE OF NAME Recorded Feb 1, 2019
From: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 048228/0619 →
CHANGE OF NAME Recorded Feb 11, 2015
From: MITSUBISHI CHEMICAL MEDIENCE CORPORATION
To: LSI MEDIENCE CORPORATION
Reel/Frame 034947/0277 →
MERGER Recorded Dec 1, 2010
From: MITSUBISHI KAGAKU IATRON, INC.
To: MITSUBISHI CHEMICAL MEDIENCE CORPORATION
Reel/Frame 025434/0458 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CO-ASSIGNEE'S NAME PREVIOUSLY RECORDED ON REEL 019352 FRAME 0718. ASSIGNOR(S) HEREBY CONFIRMS THE PROPER NAME IS JURIDICAL FOUNDATION THE CHEMO-SERO- THERAPEUTIC RESEARCH INSITUTE. Recorded Sep 13, 2007
From: ONO, TOMOKO; SOEJIMA, KENJI; HIRASHIMA, MASAKI; MORIKAWA, WATARU; SAKATA, YOICHI
To: MITSUBISHI KAGAKU IATRON, INC.; JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 019822/0695 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2007
From: ONO, TOMOKO; SOEJIMA, KENJI; HIRASHIMA, MASAKI; MORIKAWA, WATARU; SAKATA, YOICHI
To: MITSUBISHI KAGAKU IATRON, INC.; KIKUCHI RESEARCH CENTER, JURIDICAL FOUNDATION
Reel/Frame 019352/0718 →